| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
The primary target of NMT-IN-1 is N-myristoyltransferase (NMT), an enzyme that catalyzes the attachment of myristic acid to proteins. The compound inhibits TbNMT with an IC₅₀ of 31 µM and hNMT with an IC₅₀ of 66 µM. NMT is an essential enzyme in trypanosomes, making it a validated drug target for African trypanosomiasis.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that NMT-IN-1 is a potent NMT inhibitor. The compound shows IC₅₀ values of 31 µM for TbNMT and 66 µM for hNMT. NMT-IN-1 has been identified as a potential compound for the treatment of African trypanosomiasis. These activities support its potential for further investigation.
|
| ln Vivo |
In vivo activity of NMT-IN-1 has been studied in the context of African trypanosomiasis. The compound has been identified as a potential treatment for this disease. Specific in vivo data have been reported in the literature. Further studies are needed to fully characterize its in vivo efficacy.
|
| Enzyme Assay |
For NMT inhibition assays, recombinant NMT enzyme is incubated with a myristoyl-CoA substrate and a peptide substrate in the presence of NMT-IN-1. Enzyme activity is measured, and IC₅₀ values are calculated. For anti-parasitic activity screening, T. brucei parasites are cultured and treated with serial dilutions of the compound.
|
| Cell Assay |
For in vitro cell-based studies, T. brucei parasites are cultured in appropriate media and treated with serial dilutions of NMT-IN-1. Parasite growth is assessed, and IC₅₀ values are calculated. Cytotoxicity against mammalian cells is assessed in parallel.
|
| Animal Protocol |
In vivo animal studies for NMT-IN-1 have been conducted in models of African trypanosomiasis. The compound is administered via oral or intraperitoneal routes. Efficacy endpoints include reduction in parasite burden and survival.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of NMT-IN-1 have not been extensively characterized. As a small molecule with a molecular weight of 270.35 g/mol, it is expected to have reasonable membrane permeability. Specific PK parameters such as half-life and bioavailability have not been reported. Further studies are needed.
|
| Toxicity/Toxicokinetics |
Toxicological data for NMT-IN-1 are limited. As a research compound, standard toxicological studies have not been extensively published. Cytotoxicity against mammalian cell lines has been assessed. Safety assessments would be needed for therapeutic development.
|
| References | |
| Additional Infomation |
NMT-IN-1 is a research compound for the treatment of African trypanosomiasis. It is a potent NMT inhibitor. The compound inhibits both TbNMT and hNMT. No clinical trials have been reported. NMT-IN-1 serves as a lead for the development of new treatments for African trypanosomiasis.
|
| Molecular Formula |
C15H14N2OS
|
|---|---|
| Molecular Weight |
270.349462032318
|
| Exact Mass |
270.082
|
| CAS # |
326879-46-3
|
| PubChem CID |
3863359
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.3
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
19
|
| Complexity |
317
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S1CC(=O)N(CC2=NC=CC=C2)C1C1=CC=CC=C1
|
| InChi Key |
OUFWVMWVSGJVGV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H14N2OS/c18-14-11-19-15(12-6-2-1-3-7-12)17(14)10-13-8-4-5-9-16-13/h1-9,15H,10-11H2
|
| Chemical Name |
2-phenyl-3-(pyridin-2-ylmethyl)-1,3-thiazolidin-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6989 mL | 18.4945 mL | 36.9891 mL | |
| 5 mM | 0.7398 mL | 3.6989 mL | 7.3978 mL | |
| 10 mM | 0.3699 mL | 1.8495 mL | 3.6989 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
